CRVS vs KMB · $1.04B cap vs P/E 19, rev $8.35B
Corvus Pharmaceuticals Inc (CRVS) versus Kimberly-Clark Corporation (KMB) — a side-by-side from cached financials, not a winner call.
Corvus Pharmaceuticals Inc (CRVS) is a biotechnology company listed on US.
Kimberly-Clark Corporation (KMB) is a household & personal products company listed on US.
CRVS does not have a complete income-statement cache yet.
Latest reported KMB revenue for 2026-06-30 was $8.35B. Net income was $1.01B. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
CRVS currently screens at market cap $1.04B. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
Not investment advice. Open the CRVS and KMB stock pages for the full models.
Not investment advice.